TRIUMPH-4 retatrutide Phase 3 trial design — Phase 3 outcomes pending; Phase 2 data (PMID 37366315) shows up to 24.2% mean weight reduction at 48 weeks (12 mg).
TRIUMPH-4 retatrutide Phase 3 trial design — Phase 3 outcomes pending; Phase 2 data (PMID 37366315) shows up to 24.2% mean weight reduction at 48 weeks (12 mg).